SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Hervé Lebrec, Rafael Ponce, Bradley D. Preston, Jan Iles, Teresa L. Born, Michele Hooper, Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk, Current Medical Research & Opinion, 2015, 31, 3, 557

    CrossRef

  2. 2
    K. Hellgren, K. E. Smedby, C. Backlin, C. Sundstrom, N. Feltelius, J. K. Eriksson, E. Baecklund, J. Askling, Ankylosing Spondylitis, Psoriatic Arthritis, and Risk of Malignant Lymphoma: A Cohort Study Based on Nationwide Prospectively Recorded Data From Sweden, Arthritis & Rheumatology, 2014, 66, 5
  3. 3
    Millie D. Long, Susan Hutfless, Michael D. Kappelman, Hamed Khalili, Gilaad G. Kaplan, Charles N. Bernstein, Jean Frederic Colombel, Corinne Gower-Rousseau, Lisa Herrinton, Fernando Velayos, Edward V. Loftus, Geoffrey C. Nguyen, Ashwin N. Ananthakrishnan, Amnon Sonnenberg, Andrew Chan, Robert S. Sandler, Ashish Atreja, Samir A. Shah, Kenneth J. Rothman, Neal S. Leleiko, Renee Bright, Paolo Boffetta, Kelly D. Myers, Bruce E. Sands, Challenges in Designing a National Surveillance Program for Inflammatory Bowel Disease in the United States, Inflammatory Bowel Diseases, 2014, 20, 2, 398

    CrossRef

  4. 4
    Mark T. Osterman, William J. Sandborn, Jean-Frederic Colombel, Anne M. Robinson, Winnie Lau, Bidan Huang, Paul F. Pollack, Roopal B. Thakkar, James D. Lewis, Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease, Gastroenterology, 2014, 146, 4, 941

    CrossRef

  5. 5
    Zain Kassam, Sara Belga, Idan Roifman, Simon Hirota, Humberto Jijon, Gilaad G. Kaplan, Subrata Ghosh, Paul L. Beck, Inflammatory Bowel Disease Cause-specific Mortality, Inflammatory Bowel Diseases, 2014, 20, 12, 2483

    CrossRef

  6. 6
    Clément Lahaye, Zuzana Tatar, Jean-Jacques Dubost, Martin Soubrier, Overview of biologic treatments in the elderly, Joint Bone Spine, 2014,

    CrossRef

  7. 7
    S. Ramiro, C. Gaujoux-Viala, J. L. Nam, J. S. Smolen, M. Buch, L. Gossec, D. van der Heijde, K. Winthrop, R. Landewe, Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis, Annals of the Rheumatic Diseases, 2014, 73, 3, 529

    CrossRef

  8. 8
    T. Lequerré, G. Avenel, O. Vittecoq, Actualités thérapeutiques dans la polyarthrite rhumatoïde, La Revue de Médecine Interne, 2013, 34, 12, 754

    CrossRef

  9. 9
    Ruth López-González, Olga Martínez-González, Factores asociados al desarrollo de efectos secundarios en pacientes con artritis reumatoide tratados con anti-factor de necrosis tumoral alfa, Seminarios de la Fundación Española de Reumatología, 2013, 14, 3, 69

    CrossRef

  10. 10
    Antonella Di Cesare, Assunta Riitano, Mariano Suppa, Rosaria Fidanza, Arianna Zangrilli, Maria Esposito, Maria Concetta Fargnoli, Sergio Chimenti, Ketty Peris, Frequency of melanocytic nevi in psoriatic patients is related to treatment and not to disease severity, Journal of the American Academy of Dermatology, 2013, 69, 6, 947

    CrossRef

  11. 11
    Laura E Targownik, Charles N Bernstein, Infectious and Malignant Complications of TNF Inhibitor Therapy in IBD, The American Journal of Gastroenterology, 2013, 108, 12, 1835

    CrossRef

  12. 12
    T A Hammad, G A Neyarapally, S Iyasu, J A Staffa, G Dal Pan, The Future of Population-Based Postmarket Drug Risk Assessment: A Regulator's Perspective, Clinical Pharmacology & Therapeutics, 2013, 94, 3
  13. 13
    Esi Morgan DeWitt, Hermine I. Brunner, The landscape of comparative effectiveness research in rheumatology, Nature Reviews Rheumatology, 2013, 10, 1, 57

    CrossRef